Denali Therapeutics (DNLI) Competitors $21.93 +0.26 (+1.20%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DNLI vs. QGEN, PCVX, ASND, ROIV, RVMD, LNTH, BPMC, BBIO, LEGN, and ELANShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Qiagen Vaxcyte Ascendis Pharma A/S Roivant Sciences Revolution Medicines Lantheus Blueprint Medicines BridgeBio Pharma Legend Biotech Elanco Animal Health Qiagen (NYSE:QGEN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking. Do analysts recommend QGEN or DNLI? Qiagen presently has a consensus price target of $51.50, suggesting a potential upside of 11.96%. Denali Therapeutics has a consensus price target of $38.91, suggesting a potential upside of 77.42%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56Denali Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.93 Which has higher earnings and valuation, QGEN or DNLI? Qiagen has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.97B5.34$341.30M$0.39117.94Denali Therapeutics$330.53M9.55-$145.22M-$2.76-7.95 Which has more risk & volatility, QGEN or DNLI? Qiagen has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Is QGEN or DNLI more profitable? Qiagen has a net margin of 4.73% compared to Denali Therapeutics' net margin of 0.00%. Qiagen's return on equity of 13.43% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.73% 13.43% 8.10% Denali Therapeutics N/A -32.94%-30.04% Does the MarketBeat Community believe in QGEN or DNLI? Denali Therapeutics received 208 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.11% of users gave Denali Therapeutics an outperform vote while only 60.73% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.73% Underperform Votes16139.27% Denali TherapeuticsOutperform Votes45768.11% Underperform Votes21431.89% Does the media refer more to QGEN or DNLI? In the previous week, Qiagen had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 13 mentions for Qiagen and 11 mentions for Denali Therapeutics. Qiagen's average media sentiment score of 0.73 beat Denali Therapeutics' score of 0.45 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in QGEN or DNLI? 70.0% of Qiagen shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 7.9% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryQiagen beats Denali Therapeutics on 10 of the 19 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16B$2.96B$5.36B$9.14BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-7.9545.5689.4717.33Price / Sales9.55384.371,263.70136.49Price / CashN/A192.9043.7535.97Price / Book2.963.975.324.80Net Income-$145.22M-$41.02M$122.60M$224.91M7 Day Performance14.82%7.15%0.69%1.77%1 Month Performance-5.56%5.53%1.55%2.22%1 Year Performance28.10%4.90%27.25%20.67% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.4114 of 5 stars$21.93+1.2%$38.91+77.4%+28.1%$3.16B$330.53M-7.95430Analyst ForecastShort Interest ↑QGENQiagen4.0945 of 5 stars$45.90+2.7%$51.50+12.2%-0.2%$10.47B$1.97B117.695,967Short Interest ↓News CoveragePCVXVaxcyte1.9841 of 5 stars$80.35-0.9%$145.71+81.3%+35.7%$10.01BN/A-17.47160Insider TradeAnalyst RevisionNews CoverageASNDAscendis Pharma A/S3.6129 of 5 stars$131.72+2.0%$192.07+45.8%-3.2%$7.99B$327.43M-16.30640Short Interest ↓ROIVRoivant Sciences3.6806 of 5 stars$10.67+0.4%$17.93+68.0%+3.6%$7.77B$129.13M1.89860Insider TradeOptions VolumePositive NewsRVMDRevolution Medicines4.4701 of 5 stars$42.24+1.1%$66.25+56.8%+50.2%$7.11B$742,000.00-11.77250News CoverageLNTHLantheus4.5418 of 5 stars$94.41-1.5%$131.86+39.7%+65.5%$6.56B$1.50B15.71700Analyst ForecastShort Interest ↑BPMCBlueprint Medicines1.6641 of 5 stars$100.10+14.5%$122.72+22.6%+38.6%$6.36B$434.42M-47.44640Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionBBIOBridgeBio Pharma4.0863 of 5 stars$32.69+12.4%$48.08+47.1%-8.5%$6.18B$217.77M-13.56400Short Interest ↑High Trading VolumeLEGNLegend Biotech2.5041 of 5 stars$31.78-5.5%$80.62+153.7%-45.5%$5.80B$520.18M-33.451,800Short Interest ↓News CoverageELANElanco Animal Health4.415 of 5 stars$11.55+1.0%$16.43+42.2%-18.8%$5.71B$4.45B28.889,800 Related Companies and Tools Related Companies Qiagen Competitors Vaxcyte Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Revolution Medicines Competitors Lantheus Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Legend Biotech Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DNLI) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
